{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"The incidence of anti-rHuPH20 antibodies were summarized for all participants who received at least one dose of Dara-SC and had appropriate plasma samples for detection of antibodies to rHuPH20 (at least 1 sample after the start of the first dose of Dara-SC). This outcome measure was planned to be analyzed for specified arm only.","groups":[{"description":"Participants received daratumumab 1800 mg by SC injection (Dara-SC) on Days 1, 8, 15, 22 of Cycle 1 and 2, Days 1 and 15 of Cycle 3-6, and on Day 1 from Cycle 7 onwards. Participants received carfilzomib 20 mg/m\\^2 IV on Cycle 1 Day 1 and then 70 mg/m\\^2 on Cycle 1 Days 8 and 15, and Days 1, 8 and 15 from Cycle 2 onwards. Participants received dexamethasone 20 mg on Cycle 1 Days 1 and 2 and 40 mg IV or orally on Days 8, 15, 22 of Cycle 1. Participants then received dexamethasone 40 mg IV or orally on Days 1, 8, 15 and 22 of Cycles 2-9, then on Days 1, 8, 15 from Cycle 10 onwards, until confirmed PD, death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study, whichever occurs first. Each cycle of 28 days.","id":"OG000","title":"Arm B: Dara-SC in Combination With Kd (DKd)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The immunogenicity analysis set for dara-SC included all randomized participants who had appropriate samples for detection of the antibodies.","reportingStatus":"POSTED","timeFrame":"Up to end of study; up to 30.3 months","title":"Number of Participants With Anti-recombinant Human Hyaluronidase (rHuPH20) Antibodies","type":"SECONDARY","unitOfMeasure":"Participants"}